Cannabis Addiction Treatment in Arizona.

Cannabis rehab is structured behavioral treatment for cannabis use disorder, the chronic clinical condition that develops when regular cannabis use produces clinically significant impairment or distress and the using continues despite consequences. At Pinnacle Peak Recovery in Scottsdale, AZ, cannabis treatment is delivered through residential, partial hospitalization, and intensive outpatient programming for adults. The program does not treat adolescents, and the clinical work is calibrated to the current high-potency-THC product market rather than to the lower-potency cannabis flower picture of a decade ago.

If you are reading this for someone you love, the conversation often starts with the question of whether cannabis use disorder is even a real diagnosis. It is, and the picture has changed meaningfully as the product market has shifted toward concentrates, vape oils, and edibles with concentrated THC. The clinical name is cannabis use disorder. The shorthand most families use is cannabis addiction or marijuana addiction. The rest of this page covers what the disorder looks like clinically, what makes the high-potency landscape different, the cannabis-induced psychotic picture and the cannabinoid hyperemesis picture that often go undiagnosed, and what treatment looks like at Pinnacle Peak.

Is cannabis really addictive?

Roughly nine percent of adult cannabis users develop cannabis use disorder over the course of their using, and the rate is higher for people who started as adolescents and for people using high-potency products, per the NIDA Research Report on Marijuana and the DSM-5 epidemiology data in Hasin et al. (AJP, 2016) from the National Epidemiologic Survey on Alcohol and Related Conditions-III. The DSM-5-TR has recognized cannabis use disorder as a clinical diagnosis since 2013 and added cannabis withdrawal as a recognized clinical syndrome alongside it. Both pieces are commonly missed in mainstream conversations about cannabis because the older picture (lower-potency flower, primarily smoked) produced a clinical signal weaker than what the current market produces.

The DSM-5-TR criteria parallel the rest of the substance use disorder framework: using more or longer than intended, persistent unsuccessful efforts to cut down, significant time spent obtaining or using or recovering, cravings, failure to fulfill major obligations, continued use despite social or interpersonal problems, giving up activities that used to matter, recurrent use in physically hazardous situations, continued use despite physical or psychological harm, tolerance, and withdrawal. Two or three criteria meets mild, four or five moderate, six or more severe.

The reframe most clients on the iatrogenic fence find useful: the clinical question is not whether cannabis is addictive in the abstract but whether the using has reorganized the rest of their life around it. By the time someone is searching for cannabis rehab, that pattern has usually been clear to them or to someone close to them for a while.

What changed: the high-potency-THC transformation

The cannabis available in Arizona dispensaries and on the illicit market today is not the cannabis the clinical literature of twenty years ago described. Three categories of products now dominate the market, and each one has a different clinical implication.

Cannabis flower has itself increased in average THC content from roughly five to seven percent in the 1990s to fifteen to twenty-five percent in current commercial products, per Mehmedic et al.'s analysis of 46,211 confiscated samples (J Forensic Sci, 2010) and the NIDA Research Report on Marijuana. The same volume of consumption now delivers two to four times the THC a comparable user would have absorbed a generation ago.

Concentrates (wax, shatter, dab, rosin, live resin) routinely contain seventy to ninety-five percent THC and are typically vaporized through a dab rig or vape pen. The dose-per-use is qualitatively different from flower, and the speed of onset is faster. The clinical signal of a "concentrate user" presenting for treatment is meaningfully different from the clinical signal of a "flower user" with the same hours-per-day pattern.

Edibles with concentrated THC produce delayed-onset effects and a longer duration than inhaled cannabis, which produces a different intoxication pattern and a different overuse risk profile. The acute psychiatric presentations (panic, dissociation, cannabis-induced psychotic features) are most often associated with high-dose edible exposures.

The clinical implication for treatment is that the page cannot use the older lower-potency framework when describing what cannabis use disorder looks like in a current client. The withdrawal pattern is more pronounced. The psychiatric overlay is more common. The physical clinical features (including cannabinoid hyperemesis syndrome below) are more frequent. The treatment plan adjusts to which product class the client was using and at what intensity.

Why cannabis rehab does not start with detox

Cannabis withdrawal is uncomfortable but not medically dangerous. The DSM-5-TR cannabis withdrawal syndrome includes irritability, anxiety, sleep disruption (vivid dreams, insomnia), decreased appetite, restlessness, depressed mood, and physical symptoms like abdominal pain, tremor, sweating, fever, chills, or headache. Symptoms typically appear within the first week of cessation and resolve over one to two weeks for most clients, with sleep disruption sometimes persisting longer.

There is no seizure risk in cannabis withdrawal. There is no autonomic instability. There is no requirement for medical stabilization. For these reasons, medical detox is rarely clinically necessary for cannabis use disorder, and most clients enter directly into residential, partial hospitalization, or intensive outpatient programming. The exception is when polysubstance use, active cannabis-induced psychosis, severe psychiatric decompensation, or active cannabinoid hyperemesis syndrome drives a real medical-monitoring indication, in which case the medical detox program is the entry point. For most clients, it is not.

The other piece of the no-detox framing that often comes up on the first call is that cannabis cessation does not require a slow taper the way benzodiazepine or alcohol cessation does. Stopping abruptly is uncomfortable but not dangerous. The clinical work begins on day one of treatment.

Cannabis-induced psychosis and the psychiatric picture

The psychiatric clinical feature that most distinguishes cannabis treatment from the cannabis treatment of two decades ago is the increasing prevalence of cannabis-induced psychotic symptoms in heavy users of high-potency products. The presentation ranges from brief psychotic episodes during active use (paranoia, perceptual disturbances, disorganized thinking) that resolve over hours, to persistent symptoms that continue into early abstinence over days to weeks, to full psychotic disorders unmasked by heavy cannabis use that require longer-term psychiatric management. The dose-response relationship between heavy cannabis use and psychosis risk is laid out in Marconi et al.'s meta-analysis of 66,816 individuals (Schizophr Bull, 2016), which found an odds ratio of 3.9 for psychosis among the heaviest cannabis users compared to nonusers.

The substance-induced versus primary-disorder distinction is the central clinical question for cannabis clients presenting with psychotic features at intake. Substance-induced symptoms typically resolve with sustained abstinence; a primary psychotic disorder unmasked by cannabis use often becomes more apparent during early abstinence as the cannabis effect clears and the underlying picture emerges. The clinical assessment at intake distinguishes these patterns over the first weeks of treatment, and the treatment plan adjusts accordingly. Antipsychotic medication is part of the picture for clients with persistent symptoms during early abstinence.

Co-occurring depression and anxiety are common in cannabis use disorder, often more common than in some other substance classes. The clinical question is similar to the cannabis-induced psychosis question: is the depression or anxiety primary (preceded the cannabis use and was perhaps driving it) or substance-induced (developed during chronic cannabis exposure and may resolve with abstinence). The clinical assessment over the first weeks distinguishes these. For clients whose depression or anxiety persists into stable abstinence, antidepressant medication and structured cognitive therapy are part of the treatment plan. The integrated framework is covered on the dual-diagnosis treatment page.

For clients whose cannabis use began as self-medication for an underlying mental health condition (anxiety, insomnia, ADHD, post-traumatic stress symptoms), the post-cessation work includes establishing non-cannabis management of the underlying condition. Cognitive behavioral therapy is the well-evidenced first-line approach for chronic anxiety and insomnia, and the post-cessation period is the right window to establish that work rather than reaching for cannabis again to manage the symptoms.

Cannabinoid hyperemesis syndrome

A clinical feature of long-term heavy cannabis use that is often missed at the primary care or emergency department level is cannabinoid hyperemesis syndrome (CHS). The syndrome presents as cyclic vomiting, severe abdominal pain, and a distinctive compulsive use of hot showers or baths to relieve the symptoms, with cessation of cannabis as the only durable treatment, per Sorensen et al.'s systematic review (J Med Toxicol, 2017). The hot-shower piece is the diagnostic feature most clinicians outside addiction medicine miss, and clients often cycle through emergency departments with negative workups before the cannabis connection is identified.

The mechanism is not fully understood. The leading hypothesis is that long-term saturation of cannabinoid receptors disrupts the normal anti-emetic role those receptors play, producing the paradoxical hyperemesis pattern in heavy users. Anti-emetic medications typically do not work for CHS; the only durable treatment is sustained cannabis cessation. Symptoms typically begin to resolve within days to weeks of stopping and fully resolve within months for most clients.

Clients with active CHS at intake are managed with hydration support, anti-nausea medication where it provides any relief, and symptom care alongside the start of behavioral treatment. The CHS resolution is one of the more visible early-recovery wins for these clients, and naming the syndrome explicitly often produces real relief because clients have frequently been cycling through medical settings without a coherent diagnosis.

What residential and outpatient treatment look like for clients struggling with cannabis use disorder

The clinical work for cannabis use disorder is behavioral and integrated-psychiatric rather than medical. The standard length of stay in residential at Pinnacle Peak is up to thirty days, with the actual length determined by clinical need and what insurance authorizes. The schedule is structured around individual therapy, group therapy, psychoeducation about the high-potency cannabis landscape, and integrated psychiatric care for clients with co-occurring depression, anxiety, or psychotic features.

Cognitive behavioral therapy and motivational interviewing are well-supported and run consistently through residential and step-down programming. Contingency-management principles (positive reinforcement for objective evidence of treatment-aligned behavior, particularly negative urine drug screens) have evidence in cannabis use disorder treatment specifically and are part of the clinical toolkit. The Matrix Model adaptation that has the strongest evidence base for stimulant use disorder also applies usefully to cannabis use disorder, particularly the structured-relapse-prevention components.

For clients with cannabis use disorder, the trauma histories that most often shape the clinical picture include adolescent adversity, sexual trauma, and military or first-responder service where the cannabis use began as self-medication for the trauma response. The clinical team works trauma into programming where it is part of the picture; for a fuller treatment of the integrated trauma-and-substance-use framework, the dual-diagnosis page is the dedicated reference.

The step-down sequence after residential is partial hospitalization for two to four weeks, then intensive outpatient for four to eight weeks at five sessions per week, then ongoing outpatient. For clients without active psychotic features and with a recovery-supportive home environment, PHP or IOP can be the right entry point without a residential phase first. The clinical assessment at intake walks through which level fits. The general level-of-care framework is covered in inpatient versus outpatient rehab and PHP versus IOP.

What people worry about that is specific to cannabis

"Cannabis is legal, so it cannot really be a problem." Legal status is independent of clinical severity. Alcohol is legal and is the most common substance use disorder clinically. Cannabis being legal in Arizona for medical use since 2010 and for recreational use since the passage of Proposition 207 in 2020 has made high-potency products widely available, which has increased the prevalence of cannabis use disorder, not decreased it. The clinical question is the relationship between the using and the rest of the client's life, not the legal status of the substance.

"My doctor recommended medical cannabis." Medical recommendation does not preclude use disorder development, particularly when the recommended product is a high-potency concentrate or when the using extends well past the original therapeutic indication. The clinical pathway at Pinnacle Peak treats medical-recommendation clients with the same protocol as recreational clients; the destigmatizing language for clients on the medical-cannabis pathway parallels the iatrogenic-pathway framing on the benzodiazepine treatment page.

"FMLA and confidentiality." Treatment for substance use disorder is protected by federal 42 CFR Part 2 confidentiality rules in addition to HIPAA, which means treatment records cannot be released to most third parties without explicit written consent. Most employer-sponsored situations are covered by FMLA. Admissions walks through the specifics on the first call.

Insurance and cost framing

Most major commercial insurance plans cover treatment for cannabis use disorder at the residential, partial hospitalization, and intensive outpatient levels of care. Pinnacle Peak admissions runs a full benefits verification before any commitment, and the insurance hub covers the per-carrier picture in more detail.

The insurance picture for cannabis specifically tends to authorize residential, PHP, or IOP based on the clinical picture (severity of use disorder, co-occurring conditions, prior treatment history) rather than on a withdrawal-management indication. The conversation with the carrier centers on the behavioral-treatment necessity and the co-occurring psychiatric picture rather than on detox medical necessity.

The first call is a clinical assessment. It covers the using history (what products, how often, started when, current pattern, polysubstance use, co-occurring symptoms), the medical picture (CHS, any cannabis-induced psychotic episodes, other), and the level of care that fits. The call is not a commitment.

The Arizona context

The Arizona-specific consideration that shapes the clinical picture beyond the legal-status framing covered in the worry section above is the dispensary product mix. Arizona dispensaries carry the full range of high-potency concentrates, vape oils, and edibles described earlier on this page; for a client whose using began with flower and progressed to concentrates over the past few years, the clinical signal at intake reflects that escalation rather than the lower-potency picture older clinical literature describes. Current dispensary, cardholder, and licensing figures are tracked by the Arizona Department of Health Services Marijuana Program.

The polysubstance reality is the other piece. Cannabis in the Arizona supply (dispensary or illicit) is often used alongside other substances in patterns the intake screening covers explicitly. Polysubstance presentations are common in cannabis use disorder treatment and are addressed in the treatment plan from intake forward.

Frequently asked questions about cannabis rehab

What does cannabis rehab look like at Pinnacle Peak Recovery?+

Cannabis rehab at Pinnacle Peak is behavioral treatment for cannabis use disorder. The pathway is residential, PHP, or IOP rather than medical detox; cannabis withdrawal is uncomfortable but not medically dangerous, so the clinical work begins on day one rather than after a stabilization stay. The program centers on cognitive behavioral therapy, motivational interviewing, contingency-management principles, and integrated psychiatric care for the co-occurring depression, anxiety, or cannabis-induced psychotic symptoms that often accompany heavy long-term high-potency cannabis use.

Is cannabis really addictive?+

Roughly nine percent of adult cannabis users develop cannabis use disorder, and the rate is higher for people who started using as adolescents and for people using high-potency products (concentrates, vape oils, edibles with concentrated THC). The DSM-5-TR has recognized cannabis use disorder as a clinical diagnosis since 2013 and cannabis withdrawal as a recognized clinical syndrome alongside it. The "cannabis is not really addictive" framing reflects the older lower-potency flower picture and does not match the current high-THC product landscape.

Why does cannabis rehab not start with detox?+

Cannabis withdrawal is uncomfortable (irritability, anxiety, sleep disruption, decreased appetite, restlessness, depressed mood) but it is not medically dangerous. There is no seizure risk, no autonomic instability, no requirement for medical stabilization. Most clients enter directly into residential, PHP, or IOP. The exception is when polysubstance use, cannabis-induced psychosis, or severe psychiatric decompensation drives a real medical-monitoring indication, in which case the medical detox program is the entry point.

What is cannabis-induced psychosis?+

Heavy use of high-potency cannabis products can produce psychotic symptoms (paranoia, hallucinations, disorganized thinking) that range from brief episodes during use to persistent symptoms that continue into early abstinence. The clinical assessment at intake distinguishes substance-induced symptoms (typically resolve with abstinence over days to weeks) from a primary psychotic disorder unmasked by heavy cannabis use (requires longer-term psychiatric management). The high-THC concentrate market over the past decade has made this clinical picture more common than older clinical literature would suggest.

What about cannabinoid hyperemesis syndrome?+

Cannabinoid hyperemesis syndrome (CHS) is a syndrome of cyclic vomiting, abdominal pain, and compulsive hot showering that develops in some heavy long-term cannabis users. It is often misdiagnosed because cannabis is widely understood as anti-emetic, and the relief that comes from hot showers is a distinctive diagnostic feature. The only durable treatment is cannabis cessation; the symptoms typically resolve within weeks of stopping. Clients with active CHS at intake are managed with hydration support and symptom care alongside the start of behavioral treatment.

How do I get into cannabis treatment at Pinnacle Peak Recovery?+

Admission starts with one phone call: a brief clinical screen to confirm the right level of care, a free verification of your insurance benefits, and a level-of-care recommendation, usually within the hour. The residential campus is in Scottsdale, with the medical detox site less than three miles away, so for the Phoenix metro (Scottsdale, Phoenix, Tempe, Mesa, Chandler, Glendale, Gilbert) it is local; Pinnacle Peak also admits adults from across Arizona and out of state. Most clients arrive by car or rideshare, and admissions can walk through the route and what to bring on the first call.

Pairs well with

For the related clinical fundamentals on this site:

• Dual-diagnosis treatment
• Medical detox in Arizona
• Cocaine addiction treatment
• Meth addiction treatment
• Inpatient vs. outpatient rehab, how to choose
• PHP vs. IOP, how to choose